Full Text of SB2535 102nd General Assembly
SB2535enr 102ND GENERAL ASSEMBLY |
| | SB2535 Enrolled | | LRB102 17336 RLC 22826 b |
|
| 1 | | AN ACT concerning criminal law.
| 2 | | Be it enacted by the People of the State of Illinois,
| 3 | | represented in the General Assembly:
| 4 | | Section 5. The Pharmacy Practice Act is amended by | 5 | | changing Section 19.1 as follows: | 6 | | (225 ILCS 85/19.1) | 7 | | (Section scheduled to be repealed on January 1, 2023) | 8 | | Sec. 19.1. Dispensing opioid antagonists. | 9 | | (a) Due to the recent rise in opioid-related deaths in
| 10 | | Illinois and the existence of an opioid antagonist that can
| 11 | | reverse the deadly effects of overdose, the General Assembly
| 12 | | finds that in order to avoid further loss where possible, it is
| 13 | | responsible to allow greater access of such an antagonist to
| 14 | | those populations at risk of overdose. | 15 | | (b) Notwithstanding any general or special law to the
| 16 | | contrary, a licensed pharmacist shall may dispense an opioid | 17 | | antagonist
in accordance with written, standardized procedures | 18 | | or
protocols developed by the Department with the Department | 19 | | of
Public Health and the Department of Human Services and if | 20 | | the
procedures or protocols are filed at the pharmacy before
| 21 | | implementation and are available to the Department upon
| 22 | | request. | 23 | | (c) Before dispensing an opioid a pharmacist shall inform |
| | | SB2535 Enrolled | - 2 - | LRB102 17336 RLC 22826 b |
|
| 1 | | patients that opioids are addictive and offer to dispense an | 2 | | opioid antagonist pursuant to this
Section, a pharmacist shall | 3 | | complete a training program
approved by the Department of | 4 | | Human Services pursuant to
Section 5-23 of the Substance Use | 5 | | Disorder Act. The training program shall include, but not be
| 6 | | limited to, proper documentation and quality assurance . | 7 | | (d) For the purpose of this Section, "opioid antagonist" | 8 | | means a drug that binds to opioid receptors and blocks or | 9 | | inhibits the effect of opioids acting on those receptors, | 10 | | including, but not limited to, naloxone hydrochloride or any | 11 | | other similarly acting and equally safe drug approved by the | 12 | | U.S. Food and Drug Administration for the treatment of drug | 13 | | overdose.
| 14 | | (Source: P.A. 99-480, eff. 9-9-15; 99-642, eff. 7-28-16; | 15 | | 100-759, eff. 1-1-193 .) | 16 | | Section 10. The Illinois Controlled Substances Act is | 17 | | amended by changing Section 312 as follows:
| 18 | | (720 ILCS 570/312) (from Ch. 56 1/2, par. 1312)
| 19 | | Sec. 312. Requirements for dispensing controlled | 20 | | substances.
| 21 | | (a) A practitioner, in good faith, may dispense a Schedule
| 22 | | II controlled substance, which is a narcotic drug listed in | 23 | | Section 206
of this Act; or which contains any quantity of | 24 | | amphetamine or
methamphetamine, their salts, optical isomers |
| | | SB2535 Enrolled | - 3 - | LRB102 17336 RLC 22826 b |
|
| 1 | | or salts of optical
isomers; phenmetrazine and its salts; or | 2 | | pentazocine; and Schedule III, IV, or V controlled substances
| 3 | | to any person upon
a written or electronic prescription of any | 4 | | prescriber, dated and signed
by the
person prescribing (or | 5 | | electronically validated in compliance with Section 311.5) on | 6 | | the day when issued and bearing the name and
address of the | 7 | | patient for whom, or the owner of the animal for which
the | 8 | | controlled substance is dispensed, and the full name, address | 9 | | and
registry number under the laws of the United States | 10 | | relating to
controlled substances of the prescriber, if he or | 11 | | she is
required by
those laws to be registered. If the | 12 | | prescription is for an animal it
shall state the species of | 13 | | animal for which it is ordered. The
practitioner filling the | 14 | | prescription shall, unless otherwise permitted, write the date | 15 | | of filling
and his or her own signature on the face of the | 16 | | written prescription or, alternatively, shall indicate such | 17 | | filling using a unique identifier as defined in paragraph (v) | 18 | | of Section 3 of the Pharmacy Practice Act.
The written | 19 | | prescription shall be
retained on file by the practitioner who | 20 | | filled it or pharmacy in which
the prescription was filled for | 21 | | a period of 2 years, so as to be readily
accessible for | 22 | | inspection or removal by any officer or employee engaged
in | 23 | | the enforcement of this Act. Whenever the practitioner's or
| 24 | | pharmacy's copy of any prescription is removed by an officer | 25 | | or
employee engaged in the enforcement of this Act, for the | 26 | | purpose of
investigation or as evidence, such officer or |
| | | SB2535 Enrolled | - 4 - | LRB102 17336 RLC 22826 b |
|
| 1 | | employee shall give to the
practitioner or pharmacy a receipt | 2 | | in lieu thereof. If the specific prescription is machine or | 3 | | computer generated and printed at the prescriber's office, the | 4 | | date does not need to be handwritten. A prescription
for a | 5 | | Schedule II controlled substance shall not be issued for more | 6 | | than a 30 day supply, except as provided in subsection (a-5), | 7 | | and shall be valid for up to 90 days
after the date of | 8 | | issuance. A written prescription for Schedule III, IV or
V | 9 | | controlled substances shall not be filled or refilled more | 10 | | than 6 months
after the date thereof or refilled more than 5 | 11 | | times unless renewed, in
writing, by the prescriber. A | 12 | | pharmacy shall maintain a policy regarding the type of | 13 | | identification necessary, if any, to receive a prescription in | 14 | | accordance with State and federal law. The pharmacy must post | 15 | | such information where prescriptions are filled.
| 16 | | (a-5) Physicians may issue multiple prescriptions (3 | 17 | | sequential 30-day supplies) for the same Schedule II | 18 | | controlled substance, authorizing up to a 90-day supply. | 19 | | Before authorizing a 90-day supply of a Schedule II controlled | 20 | | substance, the physician must meet the following conditions: | 21 | | (1) Each separate prescription must be issued for a | 22 | | legitimate medical purpose by an individual physician | 23 | | acting in the usual course of professional practice. | 24 | | (2) The individual physician must provide written | 25 | | instructions on each prescription (other than the first | 26 | | prescription, if the prescribing physician intends for the |
| | | SB2535 Enrolled | - 5 - | LRB102 17336 RLC 22826 b |
|
| 1 | | prescription to be filled immediately) indicating the | 2 | | earliest date on which a pharmacy may fill that | 3 | | prescription. | 4 | | (3) The physician shall document in the medical record | 5 | | of a patient the medical necessity for the amount and | 6 | | duration of the 3 sequential 30-day prescriptions for | 7 | | Schedule II narcotics. | 8 | | (a-10) Prescribers who issue a prescription for an opioid | 9 | | shall inform the patient that opioids are addictive and that | 10 | | opioid antagonists are available by prescription or from a | 11 | | pharmacy. | 12 | | (b) In lieu of a written prescription required by this | 13 | | Section, a
pharmacist, in good faith, may dispense Schedule | 14 | | III, IV, or V
substances to any person either upon receiving a | 15 | | facsimile of a written,
signed prescription transmitted by the | 16 | | prescriber or the prescriber's agent
or upon a lawful oral | 17 | | prescription of a
prescriber which oral prescription shall be | 18 | | reduced
promptly to
writing by the pharmacist and such written | 19 | | memorandum thereof shall be
dated on the day when such oral | 20 | | prescription is received by the
pharmacist and shall bear the | 21 | | full name and address of the ultimate user
for whom, or of the | 22 | | owner of the animal for which the controlled
substance is | 23 | | dispensed, and the full name, address, and registry number
| 24 | | under the law of the United States relating to controlled | 25 | | substances of
the prescriber prescribing if he or she is | 26 | | required by those laws
to be so
registered, and the pharmacist |
| | | SB2535 Enrolled | - 6 - | LRB102 17336 RLC 22826 b |
|
| 1 | | filling such oral prescription shall
write the date of filling | 2 | | and his or her own signature on the face of such
written | 3 | | memorandum thereof. The facsimile copy of the prescription or
| 4 | | written memorandum of the oral
prescription shall be retained | 5 | | on file by the proprietor of the pharmacy
in which it is filled | 6 | | for a period of not less than two years, so as to
be readily | 7 | | accessible for inspection by any officer or employee engaged
| 8 | | in the enforcement of this Act in the same manner as a written
| 9 | | prescription. The facsimile copy of the prescription or oral | 10 | | prescription
and the written memorandum thereof
shall not be | 11 | | filled or refilled more than 6 months after the date
thereof or | 12 | | be refilled more than 5 times, unless renewed, in writing, by
| 13 | | the prescriber.
| 14 | | (c) Except for any non-prescription targeted | 15 | | methamphetamine precursor regulated by the Methamphetamine | 16 | | Precursor Control Act, a
controlled substance included in | 17 | | Schedule V shall not be
distributed or dispensed other than | 18 | | for a medical purpose and not for
the purpose of evading this | 19 | | Act, and then:
| 20 | | (1) only personally by a person registered to dispense | 21 | | a Schedule V
controlled substance and then only to his or | 22 | | her patients, or
| 23 | | (2) only personally by a pharmacist, and then only to | 24 | | a person over
21 years of age who has identified himself or | 25 | | herself to the pharmacist by means of
2 positive documents | 26 | | of identification.
|
| | | SB2535 Enrolled | - 7 - | LRB102 17336 RLC 22826 b |
|
| 1 | | (3) the dispenser shall record the name and address of | 2 | | the
purchaser, the name and quantity of the product, the | 3 | | date and time of
the sale, and the dispenser's signature.
| 4 | | (4) no person shall purchase or be dispensed more than | 5 | | 120
milliliters or more than 120 grams of any Schedule V | 6 | | substance which
contains codeine, dihydrocodeine, or any | 7 | | salts thereof, or
ethylmorphine, or any salts thereof, in | 8 | | any 96 hour period. The
purchaser shall sign a form, | 9 | | approved by the Department of Financial and Professional
| 10 | | Regulation, attesting that he or she has not purchased any | 11 | | Schedule V
controlled substances within the immediately | 12 | | preceding 96 hours.
| 13 | | (5) (Blank).
| 14 | | (6) all records of purchases and sales shall be | 15 | | maintained for not
less than 2 years.
| 16 | | (7) no person shall obtain or attempt to obtain within | 17 | | any
consecutive 96 hour period any Schedule V substances | 18 | | of more than 120
milliliters or more than 120 grams | 19 | | containing codeine, dihydrocodeine or
any of its salts, or | 20 | | ethylmorphine or any of its salts. Any person
obtaining | 21 | | any such preparations or combination of preparations in | 22 | | excess
of this limitation shall be in unlawful possession | 23 | | of such controlled
substance.
| 24 | | (8) a person qualified to dispense controlled | 25 | | substances under this
Act and registered thereunder shall | 26 | | at no time maintain or keep in stock
a quantity of Schedule |
| | | SB2535 Enrolled | - 8 - | LRB102 17336 RLC 22826 b |
|
| 1 | | V controlled substances in excess of 4.5 liters for each
| 2 | | substance; a pharmacy shall at no time maintain or keep in | 3 | | stock a
quantity of Schedule V controlled substances as | 4 | | defined in excess of 4.5
liters for each substance, plus | 5 | | the additional quantity of controlled
substances necessary | 6 | | to fill the largest number of prescription orders
filled | 7 | | by that pharmacy for such controlled substances in any one | 8 | | week
in the previous year. These limitations shall not | 9 | | apply to Schedule V
controlled substances which Federal | 10 | | law prohibits from being dispensed
without a prescription.
| 11 | | (9) no person shall distribute or dispense butyl | 12 | | nitrite for
inhalation or other introduction into the | 13 | | human body for euphoric or
physical effect.
| 14 | | (d) Every practitioner shall keep a record or log of | 15 | | controlled substances
received by him or her and a record of | 16 | | all such controlled substances
administered, dispensed or | 17 | | professionally used by him or her otherwise than by
| 18 | | prescription. It shall, however, be sufficient compliance with | 19 | | this
paragraph if any practitioner utilizing controlled | 20 | | substances listed in
Schedules III, IV and V shall keep a | 21 | | record of all those substances
dispensed and distributed by | 22 | | him or her other than those controlled substances
which are | 23 | | administered by the direct application of a controlled
| 24 | | substance, whether by injection, inhalation, ingestion, or any | 25 | | other
means to the body of a patient or research subject. A | 26 | | practitioner who
dispenses, other than by administering, a |
| | | SB2535 Enrolled | - 9 - | LRB102 17336 RLC 22826 b |
|
| 1 | | controlled substance in
Schedule II, which is a narcotic drug | 2 | | listed in Section 206 of this Act,
or which contains any | 3 | | quantity of amphetamine or methamphetamine, their
salts, | 4 | | optical isomers or salts of optical isomers, pentazocine, or
| 5 | | methaqualone shall do so only upon
the issuance of a written | 6 | | prescription blank or electronic prescription issued by a
| 7 | | prescriber.
| 8 | | (e) Whenever a manufacturer distributes a controlled | 9 | | substance in a
package prepared by him or her, and whenever a | 10 | | wholesale distributor
distributes a controlled substance in a | 11 | | package prepared by him or her or the
manufacturer, he or she | 12 | | shall securely affix to each package in which that
substance | 13 | | is contained a label showing in legible English the name and
| 14 | | address of the manufacturer, the distributor and the quantity, | 15 | | kind and
form of controlled substance contained therein. No | 16 | | person except a
pharmacist and only for the purposes of | 17 | | filling a prescription under
this Act, shall alter, deface or | 18 | | remove any label so affixed.
| 19 | | (f) Whenever a practitioner dispenses any controlled | 20 | | substance except a non-prescription Schedule V product or a | 21 | | non-prescription targeted methamphetamine precursor regulated | 22 | | by the Methamphetamine Precursor Control Act, he or she
shall | 23 | | affix to the container in which such substance is sold or
| 24 | | dispensed, a label indicating the date of initial filling, the | 25 | | practitioner's
name and address, the name
of the patient, the | 26 | | name of the prescriber,
the directions
for use and cautionary |
| | | SB2535 Enrolled | - 10 - | LRB102 17336 RLC 22826 b |
|
| 1 | | statements, if any, contained in any prescription
or required | 2 | | by law, the proprietary name or names or the established name
| 3 | | of the controlled substance, and the dosage and quantity, | 4 | | except as otherwise
authorized by regulation by the Department | 5 | | of Financial and Professional Regulation. No
person shall | 6 | | alter, deface or remove any label so affixed as long as the | 7 | | specific medication remains in the container.
| 8 | | (g) A person to whom or for whose use any controlled | 9 | | substance has
been prescribed or dispensed by a practitioner, | 10 | | or other persons
authorized under this Act, and the owner of | 11 | | any animal for which such
substance has been prescribed or | 12 | | dispensed by a veterinarian, may
lawfully possess such | 13 | | substance only in the container in which it was
delivered to | 14 | | him or her by the person dispensing such substance.
| 15 | | (h) The responsibility for the proper prescribing or | 16 | | dispensing of
controlled substances that are under the | 17 | | prescriber's direct control is upon the prescriber. The | 18 | | responsibility for
the proper filling of a prescription for | 19 | | controlled substance drugs
rests with the pharmacist. An order | 20 | | purporting to be a prescription
issued to any individual, | 21 | | which is not in the regular course of
professional treatment | 22 | | nor part of an authorized methadone maintenance
program, nor | 23 | | in legitimate and authorized research instituted by any
| 24 | | accredited hospital, educational institution, charitable | 25 | | foundation, or
federal, state or local governmental agency, | 26 | | and which is intended to
provide that individual with |
| | | SB2535 Enrolled | - 11 - | LRB102 17336 RLC 22826 b |
|
| 1 | | controlled substances sufficient to
maintain that individual's | 2 | | or any other individual's physical or
psychological addiction, | 3 | | habitual or customary use, dependence, or
diversion of that | 4 | | controlled substance is not a prescription within the
meaning | 5 | | and intent of this Act; and the person issuing it, shall be
| 6 | | subject to the penalties provided for violations of the law | 7 | | relating to
controlled substances.
| 8 | | (i) A prescriber shall not pre-print or cause to be
| 9 | | pre-printed a
prescription for any controlled substance; nor | 10 | | shall any practitioner
issue, fill or cause to be issued or | 11 | | filled, a pre-printed prescription
for any controlled | 12 | | substance.
| 13 | | (i-5) A prescriber may use a machine or electronic device | 14 | | to individually generate a printed prescription, but the | 15 | | prescriber is still required to affix his or her manual | 16 | | signature. | 17 | | (j) No person shall manufacture, dispense, deliver, | 18 | | possess with
intent to deliver, prescribe, or administer or | 19 | | cause to be administered
under his or her direction any | 20 | | anabolic steroid, for any use in humans other than
the | 21 | | treatment of disease in accordance with the order of a | 22 | | physician licensed
to practice medicine in all its branches | 23 | | for a
valid medical purpose in the course of professional | 24 | | practice. The use of
anabolic steroids for the purpose of | 25 | | hormonal manipulation that is intended
to increase muscle | 26 | | mass, strength or weight without a medical necessity to
do so, |
| | | SB2535 Enrolled | - 12 - | LRB102 17336 RLC 22826 b |
|
| 1 | | or for the intended purpose of improving physical appearance | 2 | | or
performance in any form of exercise, sport, or game, is not | 3 | | a valid medical
purpose or in the course of professional | 4 | | practice.
| 5 | | (k) Controlled substances may be mailed if all of the | 6 | | following conditions are met: | 7 | | (1) The controlled substances are not outwardly | 8 | | dangerous and are not likely, of their own force, to cause | 9 | | injury to a person's life or health. | 10 | | (2) The inner container of a parcel containing | 11 | | controlled substances must be marked and sealed as | 12 | | required under this Act and its rules, and be placed in a | 13 | | plain outer container or securely wrapped in plain paper. | 14 | | (3) If the controlled substances consist of | 15 | | prescription medicines, the inner container must be | 16 | | labeled to show the name and address of the pharmacy or | 17 | | practitioner dispensing the prescription. | 18 | | (4) The outside wrapper or container must be free of | 19 | | markings that would indicate the nature of the contents. | 20 | | (l) Notwithstanding any other provision of this Act to the | 21 | | contrary, emergency medical services personnel may administer | 22 | | Schedule II, III, IV, or V controlled substances to a person in | 23 | | the scope of their employment without a written, electronic, | 24 | | or oral prescription of a prescriber. | 25 | | (Source: P.A. 99-78, eff. 7-20-15; 99-480, eff. 9-9-15; | 26 | | 100-280, eff. 1-1-18 .)
|
| | | SB2535 Enrolled | - 13 - | LRB102 17336 RLC 22826 b |
|
| 1 | | Section 99. Effective date. This Act takes effect January | 2 | | 1, 2023. |
|